“Increased Efficacy of Targeted Alpha and Beta Therapies”
- A major driving force behind the Middle East and Africa alpha and beta emitters based radiopharmaceuticals market is the increasing clinical adoption of targeted radionuclide therapies, owing to their proven efficacy in treating advanced cancers such as neuroendocrine tumors and metastatic castration-resistant prostate cancer (mCRPC). These therapies offer high precision and minimal toxicity compared to conventional treatments
- For instance, in May 2023, according to the article published by NCBI, the approved [177Lu]Lu-PSMA-617 regimen (7.4 GBq per cycle every 6 weeks for up to 6 cycles) has shown strong safety and anti-tumor efficacy in real-world use, with flexible dosing (6–9.3 GBq) and treatment intervals (4–10 weeks). This consistent clinical performance enhances physician confidence and accelerates market adoption
- Radiopharmaceuticals like Lu-177, particularly when used in peptide receptor radionuclide therapy (PRRT), have demonstrated remarkable success in the treatment of neuroendocrine tumors, delivering potent beta radiation directly to tumor sites while preserving healthy tissues—leading to improved outcomes and increased demand
- Technological advancements and clinical validation of alpha-emitting isotopes, such as Ac-225, have further propelled the market. Ac-225 has proven highly effective in targeting prostate cancer cells resistant to traditional therapies, with minimal side effects and strong therapeutic impact
